Background Given that obesity might have a potent role in the regulation of the inflammatory response of spinal or peripheral joints in axial spondyloarthritis (axSpA), the detailed relationships between obesity and disease symptoms and activity should be addressed in patients with SpA
Objectives We cross-sectionally investigated whether body mass index (BMI) is associated with parameters of disease activity and clinical manifestations in axSpA.
Methods Demographic, clinical, and radiological features and disease activity indexes from 789 axSpA patients (619 males and 170 females) were obtained from the Korean College of Rheumatology Biologics (KOBIO) registry cohort. BMI (kg/m2) was classified into normal (BMI <23.0), overweight (23.0 ≤ BMI <25.0), and obese (BMI ≥25.0). Disease activity indexes included ESR, CRP, ASDAS, BASDAI, and BASFI.
Results The mean BMI in patients with axSpA was 23.8± 13.3. 50.2% of all patients were overweight or obese. Overweight/obese female patients showed higher ESR, CRP, ASDAS-ESR, and ASDAS-CRP than normal patients (p=0.045, p=0.011, p=0.035, and p=0.029, respectively). Patients with ASDAS score ≥2.1 showed higher BMI than patients with ASDAS score <2.1 (p=0.019). A greater increase in BMI was noted in patients with syndesmophyte than in those without syndesmophyte (p<0.001). Multivariate regression analysis showed that increased BMI was closely related with presence of syndesmophyte (β=0.932, p=0.002). In addition, syndesmophyte was found to be influenced by BMI (OR=1.087, 95% CI 1.033–1.145, p=0.007)
Conclusions Our results imply that increased BMI was related with presence of syndesmophyte and in part associated with disease activity in axSpA.
Ajeganova S, Andersson ML, Hafström I; BARFOT Study Group. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (Hoboken) 2013;65:78–87.
Ottaviani S, Allanore Y, Tubach F, Forien M, Gardette A, Pasquet B, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 2012;14:R115.
Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, et al. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology (Oxford) 2014;53:875–81.
Disclosure of Interest None declared